Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry. - Wikidata - awgldk - TriplyDB

Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.

Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.

http://www.wikidata.org/entity/Q37156956

about

Robot-assisted mirror ultrasound scanning for deep venous thrombosis detection using RGB-D sensor Surveillance or no surveillance for deep venous thrombosis and outcomes of critically ill patients: A study protocol and statistical analysis plan

P2860

Q56907101-09EE7F48-CF04-4C00-A512-7D8C6FF8A3B5 Q58759349-CB600FEE-37EC-4696-8838-01FDFBDDDD5D

P2860

Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.

http://www.wikidata.org/entity/Q37156956

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 July 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of screening versus sym ...... quality improvement registry.

@en

Impact of screening versus sym ...... quality improvement registry.

@nl

type

label

Impact of screening versus sym ...... quality improvement registry.

@en

Impact of screening versus sym ...... quality improvement registry.

@nl

prefLabel

Impact of screening versus sym ...... quality improvement registry.

@en

Impact of screening versus sym ...... quality improvement registry.

@nl

P1433

Q37156956-643B841F-56B3-4A89-B68B-8CA87FACD9C9

P1476

Q37156956-327B4462-CB7C-4152-97BD-15CA808D9905

P2093

Q37156956-06A8F1CC-68D5-44E3-8E69-80CEA5A618C4

Q37156956-2471CB99-DD3B-44EA-9167-ED11C42C239D

Q37156956-29724E1A-512D-459F-A9E3-7F8773232D0C

Q37156956-983036B2-89D3-4DCF-AA40-E3B0767B58F0

Q37156956-B64A5636-3542-4DDA-84E0-072DE8878677

Q37156956-B6C06C4C-94E1-455B-8DC5-7D8EC9D4237D

P2860

Q37156956-0C57CE6C-D9CC-4B07-94DA-8514396393BC

Q37156956-0DB9AF40-3010-4A4C-A9DB-BC030EF16B45

Q37156956-1ACBF11F-CE72-4CD8-A9AA-D5A54902367C

Q37156956-27E01FFE-CDAE-44C1-8461-A4A90E97D8AA

Q37156956-2A6045EA-DBE7-4137-9E95-E66B0FE84509

Q37156956-372533FF-503F-443E-AAD7-604F425E2A59

Q37156956-45729B30-A968-4EF2-92DE-E23FCAB70C9E

Q37156956-49CA5224-2E77-49CE-953A-4B6C3146889C

Q37156956-5010C68A-9D1A-44F7-B7AD-EA7D825DE02D

Q37156956-5430D23A-3CDA-4708-A972-D0F51AF46C6B

P304

Q37156956-C4A2AEB4-18E4-431B-AECB-CF50968335E4

P31

Q37156956-1C588B49-9167-4947-AEAC-F4729244488C

P356

Q37156956-6808DE25-DE0F-4C6B-BCE8-06A0B9AA4FE2

P433

Q37156956-5A10436A-3E6A-4C33-8A83-25703D0C86FB

P478

Q37156956-19B585EB-AA0B-455D-A512-E6440A33424F

P50

Q37156956-6BF881B3-DBDD-48AA-B93E-127E8CA162A3

Q37156956-85C11516-7C27-44F6-BFBE-42A45E5D2A65

P577

Q37156956-464CF514-B354-478D-8663-061E9651E52D

P698

Q37156956-9006D0B0-9512-4C77-8C42-3962E7383FF3

P921

Q37156956-EF95BCA9-C8CF-4686-B4ED-77B40771DF5D

P932

Q37156956-E9F9000F-C7C8-48D0-90F5-5EF25FC88F6E

P356

J.JVS.2012.02.066

P1433

Journal of Vascular Surgery

P1476

Impact of screening versus sym ...... l quality improvement registry

@en

P2093

David H Stone

http://www.w3.org/2001/XMLSchema#string

Jack L Cronenwett

http://www.w3.org/2001/XMLSchema#string

Jessica B Wallaert

http://www.w3.org/2001/XMLSchema#string

Matthew S Edwards

http://www.w3.org/2001/XMLSchema#string

Philip P Goodney

http://www.w3.org/2001/XMLSchema#string

Randall R De Martino

http://www.w3.org/2001/XMLSchema#string

P2860

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Surveillance bias and deep vein thrombosis in the national trauma data bank: the more we look, the more we find.

Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.

Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial.

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Prevention of pulmonary embolism by combined modalities of thromboprophylaxis and intensive surveillance protocol.

Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted?

The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis.

P304

1045-51.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JVS.2012.02.066

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Matthew A Corriere

P577

2012-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22832263

http://www.w3.org/2001/XMLSchema#string

P921

P932

3767393

http://www.w3.org/2001/XMLSchema#string